CATCH: a prospective precision oncology trial in metastatic breast cancer
CATCH (Comprehensive Assessment of clinical feaTures and biomarkers to identify patients with advanced or metastatic breast Cancer for marker driven trials in Humans) is a prospective precision oncology program that uses genomics and transcriptomics to guide therapeutic decisions in the clinical man...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
April 22, 2021
|
| In: |
JCO precision oncology
Year: 2021, Volume: 5, Pages: 676-686 |
| ISSN: | 2473-4284 |
| DOI: | 10.1200/PO.20.00248 |
| Online Access: | Resolving-System, kostenfrei, Volltext: https://doi.org/10.1200/PO.20.00248 Verlag, kostenfrei, Volltext: https://ascopubs.org/doi/full/10.1200/PO.20.00248 |
| Author Notes: | Mario Hlevnjak, Markus Schulze, Shaymaa Elgaafary, Carlo Fremd, Laura Michel, Katja Beck, Katrin Pfütze, Daniela Richter, Stephan Wolf, Peter Horak, Simon Kreutzfeldt, Constantin Pixberg, Barbara Hutter, Naveed Ishaque, Steffen Hirsch, Laura Gieldon, Albrecht Stenzinger, Christoph Springfeld, Katharina Smetanay, Julia Seitz, Athanasios Mavratzas, Benedikt Brors, Romy Kirsten, Florian Schuetz, Stefan Fröhling, Hans-Peter Sinn, Dirk Jäger, Verena Thewes, Marc Zapatka, Peter Lichter, Andreas Schneeweiss |
| Summary: | CATCH (Comprehensive Assessment of clinical feaTures and biomarkers to identify patients with advanced or metastatic breast Cancer for marker driven trials in Humans) is a prospective precision oncology program that uses genomics and transcriptomics to guide therapeutic decisions in the clinical management of metastatic breast cancer. Herein, we report our single-center experience and results on the basis of the first 200 enrolled patients of an ongoing trial. |
|---|---|
| Item Description: | Gesehen am 27.04.2021 |
| Physical Description: | Online Resource |
| ISSN: | 2473-4284 |
| DOI: | 10.1200/PO.20.00248 |